Clinical Reference Laboratory Testing Services

3. PROPOSED ACQUISITION STRATEGY

The following draft acquisition strategy is provided for industry feedback:

1. Competition: Full and Open Competition
2. Contract Vehicle: A single-award Indefinite Delivery/Indefinite Quantity (ID/IQ) contract
3. Period of Performance: A five-year base ordering period and one five-year optional ordering period, for a total potential ordering period of ten (10) years.
4. Source Selection Process: Performance Price Tradeoff (PPT), where non-price factors are significantly more important than price.

4. DRAFT DOCUMENTS FOR REVIEW

Attached to this notice are the following DRAFT documents for industry review:

1. Draft Request for Proposal (RFP) SF 1449 – HT0015-26-R-E001
2. Exhibit A - Draft Price List_Schedule of Required Tests
3. Exhibit B - Draft Clinical Reference Laboratory Testing Services QA Matrix
4. Exhibit C -Draft Past Performance Summary Sheet
5. Exhibit D - Draft Past Performance Questionnaire
6. Exhibit E – Draft Subcontractor Teaming Partner Letter and Table
7. Attachment 1 – Draft Performance Work Statement (PWS)
8. Attachment 2 – Draft Addendum to FAR 52.212-1 (Instructions to Offerors)
9. Attachment 3 – Draft Addendum to FAR 52.212-2 (Evaluation Criteria)
10. PWS Attachment 1 – Draft Summary of DoD sites
11. PWS Attachment 2 – Draft DD Form 1423-1 System Security Plan
12. PWS Attachment 3 – Draft B2B Gateway Implementation Plan and Questionnaire
13. PWS Attachment 4 – Draft DHA CAC Request Process
14. PWS Attachment 5 – Draft Request for Common Access Card
15. PWS Attachment 6 – Draft Example of DHA Common Training Requirements
16. PWS Attachment 7 – Draft DD Form 2875_System Authorization Access Request
17. PWS Attachment 8 – Draft Performance Requirements Summary
18. PWS Attachment 9 – Draft Deliverables

5. REQUEST FOR FEEDBACK

The Government is seeking constructive feedback from industry to improve the final solicitation. Respondents are encouraged to provide comments and questions on all aspects of the draft documents, with a particular focus on:

1. The clarity, feasibility, and completeness of the requirements in the Performance Work Statement (PWS).
2. The clarity of the proposal submission instructions in the Addendum to FAR 52.212-1.
3. The clarity and achievability of the evaluation criteria in the Addendum to FAR 52.212-2.
4. Any requirements that may be ambiguous, overly restrictive, or inadvertently limit competition.
5. Industry best practices that could improve the efficiency or effectiveness of the requirement.

6. INSTRUCTIONS FOR SUBMISSION

All comments and questions must be submitted in writing via email to the primary and secondary POCs listed above no later than the Response Date in this Notice. To facilitate review, it is requested that respondents use the attached Exhibit B – DRAFT Clinical Reference Laboratory Testing Services QA Matrix.

The Government intends to review all comments and questions received. The Government may, at its discretion, publish a consolidated list of questions and answers at a later date.

The Government's objective is to finalize a solicitation that is clear, equitable, and promotes robust competition. We thank you in advance for your time and valuable input.

See attached documents.